Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Yidu Tech, Inc. ( (HK:2158) ) just unveiled an update.
Yidu Tech Inc. announced that its associate, Tianjin Happy Life Technology Co., Ltd., has successfully secured a bid for a Phase III Clinical Study Project of Recombinant Human Neurogenesis Factor (SMR001) Eye Drop from Shandong Yandu Biotechnology Co., Ltd., valued at approximately RMB55.8 million. This development underscores Yidu Tech’s commitment to improving healthcare service efficiency and accessibility through AI-driven solutions, reinforcing its position in the healthcare industry by enabling precise decision-making and accelerating pharmaceutical development.
The most recent analyst rating on (HK:2158) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Yidu Tech, Inc. stock, see the HK:2158 Stock Forecast page.
More about Yidu Tech, Inc.
Yidu Tech Inc. is a company focused on AI-powered healthcare transformation in China. It offers AI medical products and solutions aimed at making precision healthcare accessible. The company utilizes its proprietary algorithm engine, YiduCore, to create a ‘data-algorithm-scenario’ ecosystem that enhances innovation and scalability across healthcare services, pharmaceuticals, insurance, and patient care.
Average Trading Volume: 14,744,006
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.48B
Find detailed analytics on 2158 stock on TipRanks’ Stock Analysis page.